A Phase 1 interventional study of Olaratumab and Doxorubicin in Neoplasm Metastasis, sponsored by Eli Lilly and Company. Completed at 21 sites in 2 countries. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2020-05-20.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing doxorubicin in Neoplasm Metastasis — 1 open to participants now, 3 under way, none of them phase 3. Doxorubicin · Neoplasm Metastasis.
Among the 18 studies testing doxorubicin in Neoplasm Metastasis, this one is the 7th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2016, is one of 8 in phase 1, and was the 16th registered.
4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.
Browse Neoplasm Metastasis studies →1 of the 18 studies testing doxorubicin in Neoplasm Metastasis is open now, in 1 country. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Doxorubicin: first FDA approval 1974 (DOXORUBICIN HYDROCHLORIDE), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.
This study: Up to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 68 is above the median of 50 across 3,271 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 53 across the 16 interventional studies. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 18 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
72 studies in Neoplasm Metastasis by Eli Lilly and Company: 7 open now, 16 under way, 7 of them phase 3. Of 54 finished, 37 (69%) have results posted.
Among the 72 studies in Neoplasm Metastasis by Eli Lilly and Company, this one is the 35th largest by enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2016, is one of 43 in phase 1, and was the 47th registered.
Eli Lilly and Company’s Neoplasm Metastasis studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing doxorubicin in Neoplasm Metastasis, from their registry updates:
Among Eli Lilly and Company’s 72 in Neoplasm Metastasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the safety of different doses of olaratumab and to determine which dose should be used for future pediatric studies. The present study is open to children with advanced cancer or cancer that has spread to another part of the body. The study has three parts. In the first two parts, a specific dose of olaratumab will be given in 21 day cycles, followed by one of three standard chemotherapy regimens. In the third part, a specific dose of olaratumab will be given with one of three standard chemotherapy regimens in 21 day cycles. Participants will only enroll in one part.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The participant has adequate hematologic, organ, and coagulation function ≤2 weeks (14 days) prior to first dose of study drug:
Participants must have fully recovered from the acute toxic effects of all prior anticancer therapies or must adhere to post-treatment conditions as follows:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cycle 1: Olaratumab 15 mg/kg was administered IV Days 1 and 8. Cycle 2 and beyond: Olaratumab 15 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met. All cycles are 21 days.
Drug: Olaratumab · Drug: Doxorubicin
Cycle 1: Olaratumab 15 mg/kg was administered IV Days 1 and 8. Cycle 2 and beyond: Olaratumab 15 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met. All cycles are 21 days.
Drug: Olaratumab · Drug: Vincristine · Drug: Irinotecan
Cycle 1: Olaratumab 15 mg/kg was administered IV Days 1 and 8. Cycle 2 and beyond: Olaratumab 15 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met. All cycles are 21 days.
Drug: Olaratumab · Drug: Ifosfamide
Cycle 1: Olaratumab 20 mg/kg was administered IV Days 1 and 8. Cycle 2 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met. All cycles are 21 days.
Drug: Olaratumab · Drug: Doxorubicin
Cycle 1: Olaratumab 20 mg/kg was administered IV Days 1 and 8. Cycle 2 and beyond: Olaratumab 20 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met. All cycles are 21 days.
Drug: Olaratumab · Drug: Vincristine · Drug: Irinotecan
Cycle 1: Olaratumab 20 mg/kg was administered IV Days 1 and 8. Cycle 2 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met. All cycles are 21 days.
Drug: Olaratumab · Drug: Doxorubicin · Drug: Ifosfamide
Cycle 1 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met. All cycles are 21 days.
Drug: Olaratumab · Drug: Doxorubicin
Cycle 1 and beyond: Olaratumab 20 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met. All cycles are 21 days.
Drug: Olaratumab · Drug: Vincristine · Drug: Irinotecan
Cycle 1 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met. All cycles are 21 days.
Drug: Olaratumab · Drug: Ifosfamide
Olaratumab administered IV.
Also known as: LY3012207
Doxorubicin administered IV.
Vincristine administered IV.
Irinotecan administered IV.
Ifosfamide administered IV.
Number of Participants With Olaratumab Dose Limiting Toxicities (DLTs)
A dose limiting toxicity (DLT) was defined as an adverse event (AE) during the first 21 days that was possibly related to the study drug and fulfilled any of the following criteria using the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0: CTCAE Grade 3 nonhematologic toxicity, grade 4 neutropenia that lasted longer than 2 weeks, grade ≥3 thrombocytopenia complicated by hemorrhage, and any hematologic toxicity that caused a cycle delay of \>14 days.
Time frame: Parts A and B: Cycle 1 through Cycle 2 in each arm (21-day cycle); Part C: Cycle 1 only (21-day cycle)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Olaratumab Part A
Pharmacokinetics (PK): Maximum serum concentration (Cmax) data of Olaratumab was reported from available sample data.
Time frame: Cycle 1, Day 8 and Cycle 2, Days 1 and 8: 1.25 hour (h), 2.5 h, 3.5h Postdose
PK: Maximum Concentration (Cmax) of Olaratumab Part B
PK: Maximum serum concentration (Cmax) data of Olaratumab was reported from available sample data.
Time frame: Cycle 1, Day 8 and Cycle 2, Days 1 and 8: 1.25 hour (h), 2.5 h, 3.5h Postdose
PK: Maximum Concentration (Cmax) of Olaratumab Part C
Pharmacokinetics (PK): Maximum serum concentration (Cmax) data of Olaratumab was reported from available sample data.
Time frame: Cycle 1, Days 1 and 8; Cycle 2, Days 1 and 8: 1.25 hour (h), 2.5 h, 3.5h Postdose
PK: Trough Serum Minimum Concentration (Cmin) of Olaratumab Part A
PK: Trough serum concentration (Cmin) of Olaratumab was reported. A sample was collected every other cycle from cycles 1, 2, 3-25.
Time frame: Cycles 1, 2, 3-25; Day 8: 336 Hours Postdose
PK: Trough Serum Minimum Concentration (Cmin) of Olaratumab Part B
PK: Trough serum concentration (Cmin) of Olaratumab was reported. A sample was collected every other cycle from cycles 1, 2, 3-25.
Time frame: Cycles 1, 2, 3-25; Day 8: 336 Hours Postdose
PK: Trough Serum Minimum Concentration (Cmin) of Olaratumab Part C
PK: Trough serum concentration (Cmin) of Olaratumab was reported. A sample was collected every other cycle from cycles 1, 2, 3-25.
Time frame: Cycles 1, 2, 3-25; Day 8: 336 Hours Postdose
Percentage of Participants With a Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])
Objective Response Rate (ORR) is the percentage of participants achieving a confirmed best overall tumor response of CR or PR. According to RECIST v1.1, PR defined as a \>30% decrease in the sum of the longest diameters (LD) of the target lesions, taking as reference the baseline sum of the LD; CR was defined as the disappearance of all target and non-target lesions.
Time frame: Baseline to objective progression or start of new anti-cancer therapy (Up to 7 months)
Progression Free Survival (PFS)
Progression-free survival (PFS) is defined as the time from baseline to the first date of radiological disease progression or death due to any cause. Progressive disease (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). The appearance of one or more new lesions is also considered progression. If participant started new treatment before PD, the participant was censored at the date of last tumor assessment prior to new therapy. If treatment was discontinued for reasons other than PD and no further assessment, censoring occurred at last tumor assessment.
Time frame: Baseline to radiological disease progression or death from any cause (Up to 2 Years)
Percentage of Participants With Treatment Emergent (TE) Positive Anti-Olaratumab Antibodies
Percentage of participants with a TE positive anti-olaratumab antibodies defined as a participant with a 4-fold (2 dilutions) increase over a positive baseline antibody titer.
Time frame: From Baseline to Study Completion (Up to 33 Months)
| Milestone | Olaratumab + Vincristine + Irinotecan (Part A) | Olaratumab + Doxorubicin (Part A) | Olaratumab + Ifosfamide (Part A) | Olaratumab + Vincristine + Irinotecan (Part B) | Olaratumab + Doxorubicin (Part B) | Olaratumab + Ifosfamide (Part B) | Olaratumab + Vincristine + Irinotecan (Part C) | Olaratumab + Ifosfamide (Part C) | Olaratumab + Doxorubicin (Part C) |
|---|---|---|---|---|---|---|---|---|---|
| Started | 10 | 11 | 9 | 10 | 1 | 13 | 6 | 4 | 4 |
| Cycle 1 olaratumab alone | 10 | 11 | 9 | 10 | 1 | 13 | 6 | 4 | 4 |
| Progressive disease | 7 | 7 | 6 | 7 | 0 | 9 | 2 | 2 | 2 |
| Completed | 7 | 7 | 6 | 7 | 0 | 9 | 2 | 2 | 2 |
| Not completed | 3 | 4 | 3 | 3 | 1 | 4 | 4 | 2 | 2 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 2 | 3 | 2 | 1 | 3 | 1 | 1 | 2 |
| Withdrew: Withdrawal by parent or guardian | 2 | 1 | 0 | 1 | 0 | 0 | 2 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
A dose limiting toxicity (DLT) was defined as an adverse event (AE) during the first 21 days that was possibly related to the study drug and fulfilled any of the following criteria using the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0: CTCAE Grade 3 nonhematologic toxicity, grade 4 neutropenia that lasted longer than 2 weeks, grade ≥3 thrombocytopenia complicated by hemorrhage, and any hematologic toxicity that caused a cycle delay of \>14 days.
| Participants | Olaratumab + Vincristine + Irinotecan (Part A) | Olaratumab + Ifosfamide (Part A) | Olaratumab + Doxorubicin (Part A) | Olaratumab + Vincristine + Irinotecan (Part B) | Olaratumab + Ifosfamide (Part B) | Olaratumab + Doxorubicin (Part B) | Olaratumab + Vincristine + Irinotecan (Part C) | Olaratumab + Ifosfamide (Part C) | Olaratumab + Doxorubicin (Part C) |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Olaratumab Dose Limiting Toxicities (DLTs) | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 |
Pharmacokinetics (PK): Maximum serum concentration (Cmax) data of Olaratumab was reported from available sample data.
| microgram/milliliter (μg/mL) | Olaratumab Alone (Part A) | Olaratumab + Doxorubicin (Part A) | Olaratumab + Ifosfamide (Part A) | Olaratumab + Vincristine + Irinotecan (Part A) |
|---|---|---|---|---|
| Cycle 1, Day 8 | 439 ± 23 | — | — | — |
| Cycle 2, Day 1 | — | 406 ± 21 | 396 ± 39 | 437 ± 44 |
| Cycle 2, Day 8 | — | 422 ± 30 | 398 ± 44 | 523 ± 26 |
PK: Maximum serum concentration (Cmax) data of Olaratumab was reported from available sample data.
| microgram/milliliter (μg/mL) | Olaratumab Alone (Part B) | Olaratumab + Doxorubicin (Part B) | Olaratumab + Ifosfamide (Part B) | Olaratumab +Vincristine + Irinotecan (Part B) |
|---|---|---|---|---|
| Cycle 1, Day 8 | 639 ± 27 | — | — | — |
| Cycle 2, Day 1 | — | — | 629 ± 32 | 585 ± 30 |
| Cycle 2, Day 8 | — | — | 696 ± 27 | 647 ± 27 |
Pharmacokinetics (PK): Maximum serum concentration (Cmax) data of Olaratumab was reported from available sample data.
| microgram/milliliter (μg/mL) | Olaratumab + Doxorubicin Cycle 1 (Part C) | Olaratumab + Doxorubicin (Part C) | Olaratumab + Vincristine + Irinotecan (Part C) | Olaratumab + Ifosfamide (Part C) |
|---|---|---|---|---|
| Cycle 1, Day 1 | 406 ± 20 | — | 548 ± 15 | 363 ± 39 |
| Cycle 1, Day 8 | 493 ± 20 | — | 695 ± 37 | 498 ± 43 |
| Cycle 2, Day 8 | — | 502 ± 38 | 707 ± 3 | 567 ± 38 |
PK: Trough serum concentration (Cmin) of Olaratumab was reported. A sample was collected every other cycle from cycles 1, 2, 3-25.
| μg/mL | Olaratumab Alone (Part A) | Olaratumab + Doxorubicin (Part A) | Olaratumab + Ifosfamide (Part A) | Olaratumab + Vincristine + Irinotecan (Part A) |
|---|---|---|---|---|
| Cycle 1, Day 8 | 73 ± 56 | — | 46.3 ± 284 | 97.8 ± 29 |
| Cycle 2, Day 8 | — | 38.5 ± 29.1 | 114 ± 85 | 37.7 ± 112 |
| Cycle 3-25, Day 8 | — | 94.4 ± 41 | 88.2 ± 77 | 95.1 ± 85 |
PK: Trough serum concentration (Cmin) of Olaratumab was reported. A sample was collected every other cycle from cycles 1, 2, 3-25.
| μg/mL | Olaratumab Alone (Part B) | Olaratumab + Doxorubicin (Part B) | Olaratumab + Ifosfamide (Part B) | Olaratumab +Vincristine + Irinotecan (Part B) |
|---|---|---|---|---|
| Cycle 1, Day 8 | — | — | 125 ± 55 | 99.1 ± 65 |
| Cycle 2, Day 8 | — | — | 199 ± 36 | 230 ± 17 |
| Cycle 3-25, Day 8 | — | — | 289 ± 14 | 348 ± 15 |
PK: Trough serum concentration (Cmin) of Olaratumab was reported. A sample was collected every other cycle from cycles 1, 2, 3-25.
| μg/mL | Olaratumab + Doxorubicin (Part C) | Olaratumab + Vincristine + Irinotecan (Part C) | Olaratumab + Ifosfamide (Part C) |
|---|---|---|---|
| Cycle 1, Day 8 | 90.3 ± 33 | 83.7 ± 8 | 124 ± 32 |
| Cycle 2, Day 8 | 141 ± 18 | 134 ± 54 | NA ± NA |
| Cycle 3-25, Day 8 | 156 ± 24 | 83.7 ± 48 | NA ± NA |
Objective Response Rate (ORR) is the percentage of participants achieving a confirmed best overall tumor response of CR or PR. According to RECIST v1.1, PR defined as a \>30% decrease in the sum of the longest diameters (LD) of the target lesions, taking as reference the baseline sum of the LD; CR was defined as the disappearance of all target and non-target lesions.
| percentage of participants | Olaratumab + Vincristine + Irinotecan (Part A) | Olaratumab + Ifosfamide (Part A) | Olaratumab + Doxorubicin (Part A) | Olaratumab + Vincristine + Irinotecan (Part B) | Olaratumab + Ifosfamide (Part B) | Olaratumab + Doxorubicin (Part B) | Olaratumab + Vincristine + Irinotecan (Part C) | Olaratumab + Ifosfamide (Part C) | Olaratumab + Doxorubicin (Part C) |
|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With a Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) | 0 | 0 | 9.1 | 20.0 | 0 | 0 | 0 | 0 | 25.0 |
Progression-free survival (PFS) is defined as the time from baseline to the first date of radiological disease progression or death due to any cause. Progressive disease (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). The appearance of one or more new lesions is also considered progression. If participant started new treatment before PD, the participant was censored at the date of last tumor assessment prior to new therapy. If treatment was discontinued for reasons other than PD and no further assessment, censoring occurred at last tumor assessment.
| Months | Olaratumab + Vincristine + Irinotecan (Part A) | Olaratumab + Ifosfamide (Part A) | Olaratumab + Doxorubicin (Part A) | Olaratumab + Vincristine + Irinotecan (Part B) | Olaratumab + Ifosfamide (Part B) | Olaratumab + Doxorubicin (Part B) | Olaratumab + Vincristine + Irinotecan (Part C) | Olaratumab + Ifosfamide (Part C) | Olaratumab + Doxorubicin (Part C) |
|---|---|---|---|---|---|---|---|---|---|
| Progression Free Survival (PFS) | 1.54 (0.69 to 15.74) | 1.38 (0.62 to 5.68) | 1.26 (0.26 to 5.26) | 1.28 (0.53 to 11.07) | 1.25 (1.15 to 3.12) | NA (NA to NA) | 4.07 (1.41 to 4.07) | 4.88 (0.69 to 8.54) | 5.52 (1.22 to 5.52) |
Percentage of participants with a TE positive anti-olaratumab antibodies defined as a participant with a 4-fold (2 dilutions) increase over a positive baseline antibody titer.
| percentage of participants | Olaratumab + Vincristine + Irinotecan (Part A) | Olaratumab + Ifosfamide (Part A) | Olaratumab + Doxorubicin (Part A) | Olaratumab + Vincristine + Irinotecan (Part B) | Olaratumab + Ifosfamide (Part B) | Olaratumab + Doxorubicin (Part B) | Olaratumab + Vincristine + Irinotecan (Part C) | Olaratumab + Ifosfamide (Part C) | Olaratumab + Doxorubicin (Part C) |
|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Treatment Emergent (TE) Positive Anti-Olaratumab Antibodies | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over Up to 33 Months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Olaratumab + Vincristine + Irinotecan (Part A) | 2/10 (20%) | 3/10 (30%) | 10/10 (100%) |
| Olaratumab + Ifosfamide (Part A) | 1/9 (11.1%) | 4/9 (44.4%) | 9/9 (100%) |
| Olaratumab + Doxorubicin (Part A) | 2/11 (18.2%) | 2/11 (18.2%) | 11/11 (100%) |
| Olaratumab + Vincristine + Irinotecan (Part B) | 2/10 (20%) | 5/10 (50%) | 9/10 (90%) |
| Olaratumab + Ifosfamide (Part B) | 2/13 (15.4%) | 7/13 (53.8%) | 13/13 (100%) |
| Olaratumab + Doxorubicin (Part B) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Olaratumab + Vincristine + Irinotecan (Part C) | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Olaratumab + Ifosfamide (Part C) | 0/4 (0%) | 1/4 (25%) | 4/4 (100%) |
| Olaratumab + Doxorubicin (Part C) | 0/4 (0%) | 4/4 (100%) | 4/4 (100%) |
| Event | Olaratumab + Vincristine + Irinotecan (Part A) | Olaratumab + Ifosfamide (Part A) | Olaratumab + Doxorubicin (Part A) | Olaratumab + Vincristine + Irinotecan (Part B) | Olaratumab + Ifosfamide (Part B) | Olaratumab + Doxorubicin (Part B) | Olaratumab + Vincristine + Irinotecan (Part C) | Olaratumab + Ifosfamide (Part C) | Olaratumab + Doxorubicin (Part C) |
|---|---|---|---|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 0/10 | 0/9 | 0/11 | 1/10 | 6/13 | 0/1 | 1/6 | 1/4 | 2/4 |
| DiarrhoeaGastrointestinal disorders | 0/10 | 0/9 | 0/11 | 3/10 | 0/13 | 0/1 | 1/6 | 0/4 | 0/4 |
| Abdominal infectionInfections and infestations | 0/10 | 0/9 | 0/11 | 0/10 | 0/13 | 0/1 | 0/6 | 0/4 | 1/4 |
| Urinary retentionRenal and urinary disorders | 0/10 | 0/9 | 0/11 | 0/10 | 0/13 | 0/1 | 0/6 | 0/4 | 1/4 |
| AnaemiaBlood and lymphatic system disorders | 0/10 | 2/9 | 0/11 | 0/10 | 0/13 | 0/1 | 0/6 | 0/4 | 0/4 |
| DehydrationMetabolism and nutrition disorders | 0/10 | 0/9 | 0/11 | 2/10 | 0/13 | 0/1 | 0/6 | 0/4 | 0/4 |
| Staphylococcus test positiveInvestigations | 0/10 | 0/9 | 0/11 | 0/10 | 0/13 | 0/1 | 1/6 | 0/4 | 0/4 |
| Vena cava thrombosisVascular disorders | 0/10 | 0/9 | 0/11 | 0/10 | 0/13 | 0/1 | 1/6 | 0/4 | 0/4 |
| Penile infectionInfections and infestations | 0/6 | 1/7 | 0/8 | 0/4 | 0/7 | 0/1 | 0/2 | 0/3 | 0/2 |
| Urinary tract infectionInfections and infestations | 0/10 | 1/9 | 0/11 | 0/10 | 0/13 | 0/1 | 0/6 | 0/4 | 0/4 |
| Event | Olaratumab + Vincristine + Irinotecan (Part A) | Olaratumab + Ifosfamide (Part A) | Olaratumab + Doxorubicin (Part A) | Olaratumab + Vincristine + Irinotecan (Part B) | Olaratumab + Ifosfamide (Part B) | Olaratumab + Doxorubicin (Part B) | Olaratumab + Vincristine + Irinotecan (Part C) | Olaratumab + Ifosfamide (Part C) | Olaratumab + Doxorubicin (Part C) |
|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 4/10 | 7/9 | 6/11 | 5/10 | 8/13 | 0/1 | 4/6 | 3/4 | 4/4 |
| DiarrhoeaGastrointestinal disorders | 6/10 | 1/9 | 1/11 | 7/10 | 1/13 | 0/1 | 6/6 | 2/4 | 1/4 |
| NauseaGastrointestinal disorders | 5/10 | 4/9 | 4/11 | 7/10 | 9/13 | 1/1 | 2/6 | 3/4 | 3/4 |
| Alanine aminotransferase increasedInvestigations | 2/10 | 2/9 | 1/11 | 1/10 | 2/13 | 1/1 | 3/6 | 2/4 | 0/4 |
| Aspartate aminotransferase increasedInvestigations | 2/10 | 4/9 | 1/11 | 1/10 | 4/13 | 1/1 | 3/6 | 2/4 | 0/4 |
| Gamma-glutamyltransferase increasedInvestigations | 0/10 | 4/9 | 0/11 | 0/10 | 0/13 | 1/1 | 1/6 | 1/4 | 0/4 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/10 | 0/9 | 1/11 | 1/10 | 4/13 | 1/1 | 1/6 | 0/4 | 0/4 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/10 | 0/9 | 0/11 | 1/10 | 0/13 | 1/1 | 0/6 | 1/4 | 0/4 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/10 | 0/9 | 1/11 | 2/10 | 1/13 | 1/1 | 0/6 | 0/4 | 0/4 |
| FlushingVascular disorders | 0/10 | 0/9 | 0/11 | 0/10 | 0/13 | 1/1 | 1/6 | 0/4 | 0/4 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | Olaratumab + Vincristine + Irinotecan (Part A) | Olaratumab + Doxorubicin (Part A) | Olaratumab + Ifosfamide (Part A) | Olaratumab + Vincristine + Irinotecan (Part B) | Olaratumab + Doxorubicin (Part B) | Olaratumab + Ifosfamide (Part B) | Olaratumab + Vincristine + Irinotecan (Part C) | Olaratumab + Ifosfamide (Part C) | Olaratumab + Doxorubicin (Part C) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 9.9 ± 5.5 | 6.8 ± 4.3 | 10.7 ± 4.3 | 10.6 ± 4.9 | NA ± NA | 12.5 ± 3.8 | 9.7 ± 5.4 | 8.0 ± 7.0 | 10.8 ± 5.1 | 10.0 ± 4.8 |
| Sex: Female, Male(Participants) | Olaratumab + Vincristine + Irinotecan (Part A) | Olaratumab + Doxorubicin (Part A) | Olaratumab + Ifosfamide (Part A) | Olaratumab + Vincristine + Irinotecan (Part B) | Olaratumab + Doxorubicin (Part B) | Olaratumab + Ifosfamide (Part B) | Olaratumab + Vincristine + Irinotecan (Part C) | Olaratumab + Ifosfamide (Part C) | Olaratumab + Doxorubicin (Part C) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 4 | 3 | 2 | 6 | 0 | 6 | 4 | 1 | 2 | 28 |
| Male | 6 | 8 | 7 | 4 | 1 | 7 | 2 | 3 | 2 | 40 |
| Race (NIH/OMB)(Participants) | Olaratumab + Vincristine + Irinotecan (Part A) | Olaratumab + Doxorubicin (Part A) | Olaratumab + Ifosfamide (Part A) | Olaratumab + Vincristine + Irinotecan (Part B) | Olaratumab + Doxorubicin (Part B) | Olaratumab + Ifosfamide (Part B) | Olaratumab + Vincristine + Irinotecan (Part C) | Olaratumab + Ifosfamide (Part C) | Olaratumab + Doxorubicin (Part C) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 | 0 | 0 | 0 | 3 | 3 | 3 | 11 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 | 2 | 0 | 2 | 0 | 0 | 0 | 8 |
| White | 9 | 8 | 5 | 7 | 1 | 11 | 3 | 1 | 1 | 46 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 3 |
| Race/Ethnicity, Customized(Participants) | Olaratumab + Vincristine + Irinotecan (Part A) | Olaratumab + Doxorubicin (Part A) | Olaratumab + Ifosfamide (Part A) | Olaratumab + Vincristine + Irinotecan (Part B) | Olaratumab + Doxorubicin (Part B) | Olaratumab + Ifosfamide (Part B) | Olaratumab + Vincristine + Irinotecan (Part C) | Olaratumab + Ifosfamide (Part C) | Olaratumab + Doxorubicin (Part C) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 4 | 1 | 1 | 0 | 3 | 2 | 1 | 1 | 14 |
| Not Hispanic or Latino | 9 | 7 | 7 | 8 | 1 | 10 | 1 | 0 | 0 | 43 |
| Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 4 |
| Missing | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 2 | 1 | 7 |
| Region of Enrollment(Participants) | Olaratumab + Vincristine + Irinotecan (Part A) | Olaratumab + Doxorubicin (Part A) | Olaratumab + Ifosfamide (Part A) | Olaratumab + Vincristine + Irinotecan (Part B) | Olaratumab + Doxorubicin (Part B) | Olaratumab + Ifosfamide (Part B) | Olaratumab + Vincristine + Irinotecan (Part C) | Olaratumab + Ifosfamide (Part C) | Olaratumab + Doxorubicin (Part C) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| United States | 10 | 11 | 9 | 10 | 1 | 13 | 3 | 1 | 1 | 59 |
| Japan | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 3 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2016 to primary completion in Oct 2018, 25 months.
Results were first posted in May 2020, 1 year 7 months after primary completion.
Of 287 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's 25 months is below that.
Counting every sponsor, half of 497 studies reached it within 54 months; a quarter within 33 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Doxorubicin · Vincristine · Irinotecan · Ifosfamide